K Vijay Kumar*

Department of Clinical Research, Medicover Hospitals, India

*Corresponding Author: K Vijay Kumar, Department of Clinical Research, Medicover Hospitals, India.

Received: December 15, 2023; Published: January 01, 2024

Abstract

Mefenamic acid is a fenamic acid derivative of carboxylic acid, and is available worldwide as tablets (250 and 500mg), capsules (250mg) and a paediatric suspension (50 mg/5ml). Clinical Effects in Overdose Mefenamic acid is the fifth most commonly prescribed NSAID and is a common source of selfpoisoning: 8.5% of all NSAID overdoses reported in one study between 1971 and 1985 were due to mefenamic acid (McMurray., et al. 1987).

References

1. Smolinske Susan C., et al. "Toxic effects of nonsteroidal anti-inflammatory drugs in overdose: an overview of recent evidence on clinical effects and dose-response relationships". Drug Safety4 (1990): 252-274.
2. Kamour Ashraf., et al. "Central nervous system toxicity of mefenamic acid overdose compared with other NSAIDs: an analysis of cases reported to the United Kingdom National Poisons Information Service". British Journal of Clinical Pharmacology4 (2017): 855-862.
3. Madhu J and A S Shylaja. "Randomised trial of mefenamic acid versus tranexamic acid in management of menorrhagia." International Journal of Reproduction, Contraception, Obstetrics and Gynecology10 (2017): 4608-4613.

Citation

Citation: K Vijay Kumar. “The Evidence of Mefenamic Acid is Unsafe and ICP Issues Safety Alert".Acta Scientific Pharmaceutical Sciences 8.2 (2024): 01-02.

Copyright

Copyright: © 2024 K Vijay Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.